• Citer

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.

par Neven, Bénédicte;Marvillet, Isabelle;Terrada, Celine;Ferster, Alina ;Boddaert, Nathalie;Couloignier, Vincent;Pinto, Graziella;Pagnier, A;Bodemer, Christine;Bodaghi, Bahram;Tardieu, Marc;Prieur, Anne Marie;Quartier, Pierre
Référence Arthritis and rheumatism, 62, 1, page (258-267)
Publication Publié, 2010-01

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Cryopyrin-associated periodic syndromes (CAPS) are a group of rare autoinflammatory diseases. Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurologic, cutaneous, articular syndrome (CINCA syndrome) is the most severe phenotype, with fever, rash, articular manifestations, and neurologic and neurosensory involvement. CAPS are caused by mutations in CIAS1, the gene encoding NLRP3, which plays a critical role in interleukin-1 (IL-1) processing. Anakinra, an IL-1 receptor antagonist, has been shown to be an effective treatment; however, data on long-term efficacy and safety have been sparse. This study was undertaken to assess the long-term efficacy and safety of anakinra treatment in patients with NOMID/CINCA syndrome.